Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy

Official record

Identifier

NCT07829068

Recruiting locations

country

Switzerland

Interventions studied

study-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen

Lead sponsor

University Hospital, Geneva

Target enrolment

30 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Active, not recruiting

First posted

Sep 18, 2026

Last updated on the registry

Sep 30, 2026

Age

18 Years

Sex

MALE

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Diagnosis of intermediate- or high-risk prostate cancer.
* Preoperative PSMA PET staging with positive uptake in the primary tumor.
* Multidisciplinary approval by the urology tumor board for radical prostatectomy and study inclusion.
* Capacity to provide informed consent

Exclusion Criteria:

* Refusal to participate or withdrawal from the study.
* Inability to follow study procedures, for example because of language difficulties, psychological disorders or dementia.
* Participation in another clinical trial requiring ex vivo prostate tissue for research.
* Prior treatment that may alter PSMA uptake, such as androgen deprivation therapy or radiotherapy.
* Variant prostate cancer histology, such as neuroendocrine cancer.
* Insufficient-quality or unavailable PSMA PET images, including corrupted data, or an incomplete histopathology report.

Indexed under

Prostate Cancer